Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 21.30 as of Monday, August 10, 2026.
Forward PE Ratio (21.30) = Close Price ($237.60) / Consensus Forward EPS ($11.19)
FORWARD PE RATIO
21.30
SECTOR MEDIAN · HEALTHCARE
19.55
median of 69 covered companies
CURRENT VS SECTOR MEDIAN
+8.95%
vs the sector median at left
Quest Diagnostics Incorporated
Market Cap
$26.22B
Forward PE Ratio
21.30
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $26.22B | 21.30 |
| Labcorp Holdings Inc. (LH)vs › | $26.19B | 17.48 |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.04B | 39.59 |
| Incyte Corporation (INCY)vs › | $24.83B | 28.83 |
| Medline Inc. (MDLN)vs › | $28.44B | 23.03 |
| Moderna, Inc. (MRNA)vs › | $23.63B | N/A |
| BioNTech SE (BNTX)vs › | $23.47B | N/A |
| Mettler-Toledo International Inc. (MTD)vs › | $29.05B | 30.35 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.26B | 32.41 |
| STERIS plc (STE)vs › | $23.03B | 23.29 |
Trailing P/E
25.3
reported TTM EPS
Forward P/E
21.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $11.19 implies +18.8% EPS growth vs the reported trailing $9.42.
At today's $237.60 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $11.19 | $10.74 – $11.27 | 11 | 21.2x |
| 2027-12-31 | $12.06 | $11.60 – $12.36 | 11 | 19.7x |
| 2028-12-31 | $13.09 | $12.08 – $14.09 | 7 | 18.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
